MetaVia Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MetaVia presented preclinical mouse study data on November 14, 2026, showing DA-1726 (a GLP1R/GCGR dual agonist) achieved weight loss comparable to retatrutide (43.6% vs 41.7% at high dose) with less appetite suppression (41.4% vs 31.2% food intake reduction), greater glucose lowering (39.2% vs 32.5%), and significantly increased hepatic FGF21 expression (p<0.05 for gene, p<0.001 for circulating protein). The company plans to initiate a Phase 2, 48-week non-biopsy study in MetALD and ALD in H2 2027, building on Phase 1 Part 3B data showing 13.5% placebo-adjusted weight loss and 68.0% liver fat reduction.
Why this rating
Preclinical data de-risks Phase 2 initiation for lead asset at $3M-market-cap biotech; favorable differentiation vs. competitor compound strengthens clinical rationale, though early-stage risk remains.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.27 ▼ 0.78% | at our read · unknown $1.28 | +10 min · unknown $1.27 ▼ 0.78% | +30 min · unknown $1.28 ▲ 0.39% | +1 hr · unknown $1.26 ▼ 1.56% | +4 hrs · unknown $1.29 ▲ 0.78% |
The stock had already moved +0.79% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.